ERRATUM - Advicenne Reports its Financial Results for the Ye

Significant regulatory and commercial progress for SibnayalTM Control of expenses with a net loss reduced to €12.4 million (vs. €14.8 million) Closing cash position at €12.7 million.

Related Keywords

United States , Canada , Paris , France General , France , United Kingdom , French , British , Ashley Tapp , Mary Jane Elliott , Davide Salvi , Advicenne Euronext , Didier Laurens , Research Tax Credit Cr , European Commission , Drug Administration , Regulatory Agency , National Health Service , European Investment Bank , Consilium Strategic Communications , Euronext , Chief Executive Officer , Frost Pharma , Research Tax Credit , Medicines Healthcare , Haute Autorit , Eastern European , Pharma Partner , Marketing Approval , Euronext Paris , French Financial , Jane Elliott , Ferratum , Advicenne , Reports , Financial , Results , Ear , Nded , December , 021 ,